Page 23 - Pharma Industry

Alembic Pharma Q4 net up 12% to Rs 251 cr on strong API, global businesses

Net sales rise 6% to Rs 1,280 cr; API business expands by as much as 38%

State govts begin vaccine price negotiations, eye Rs 150 per dose

States would have to fund procurement from their own budgets and bridge funding from the Centre is unlikely

Pharma poised for an excellent FY22 on the back of Covid-led demand

Improving exports and a weak rupee could support profit boost

Strong injectables portfolio to support Aurobindo Pharma's growth

The stock has been underperforming recent months and trades at a discount to peers

Shortage of key chemical hits Bharat Biotech's Covaxin ramp-up plans

Bharat Biotech is trying to ramp up capacities of Covaxin to 12 million doses per month by July, from the current 5 million doses per month

Alembic Pharma's injectables plant launch may face some delay

Company saw Form 483 with observations issued by US FDA for injectables plant in February

Piramal Pharma to acquire 100% stake in Hemmo Pharma for Rs 775 cr

Consequent to the acquisition, Hemmo Pharmaceuticals Pvt Ltd would become a wholly-owned subsidiary of Piramal Pharma Ltd

Orchid Pharma rises from ashes, expects to make profits in 12 months

Dhanuka Pharmaceuticals that took over the company almost a year ago, nursed it back to health from bankruptcy

Govt okays 33 API applications with Rs 5k cr investment under PLI scheme

In total, 215 applications have been received for the 36 products spread across the 4 target segments, the Ministry of Chemicals and Fertilizers said in the release

New launches, market share gains to sustain Gland Pharma's sales trajectory

Earnings are expected to grow over 25 per cent over the next two years

Healing a weak regulator

Weaknesses in India's drug regulatory regime and the constraints and questionable decisions of the drug regulator could mar the country's reputation in global markets

Pharma stocks may hold ground as volatility grips global markets

The Nifty Pharma index was down 1.76 per cent on Friday compared to a 568-point or nearly 3.8 per cent slide in the Nifty50 on weak global cues

Make next 10 years 'the decade of India': Piyush Goyal to pharma firms

Coining a new acronym, Goyal said the world today needs CURE - Cost-effective Uni­ve­rsal solutions through Research and Enterprise

Weak Q3 show, margin pressures to keep Sanofi stock under pressure

Growth led by power brands and new launches could recover as pandemic impact wanes

PLI scheme: Pharma industry expects more guidelines on investment

B R Sikri, chairman of the Federation of Pharma Entrepreneurs, said, higher incentives would have meant more production of cancer drugs, thereby, bringing down their prices

Centre announces Rs 15,000 crore PLI for pharma, IT hardware sectors

Pharma scheme aims at Rs 3 trillion incremental sales, 100,000 jobs; experts say hardware scheme to help India become electronics manufacturing hub for the world

Asset monetisation, sales uptick in US key triggers for Glenmark Pharma

The India business is expected to post double digit growth in FY22

Govt has decided to shut 2 pharma PSUs, disinvest other 3: Govt tells LS

The government has decided to close two pharma public sector undertakings and disinvest the other three, Parliament was informed on Tuesday. "The Department of Pharmaceuticals has five public sector undertakings (PSUs). Out of the five PSUs, the government has taken a decision to close two pharma PSUs, namely Indian Drugs & Pharmaceuticals Ltd (IDPL) and Rajasthan Drugs & Pharmaceuticals Ltd (RDPL)," Minister ofChemicals and Fertilisers D V Sadananda Gowda said in response to a question in the Lok Sabha. The government has also decided to strategically disinvestthe other three -- Hindustan Antibiotics Ltd (HAL), Bengal Chemicals & Pharmaceuticals Ltd (BCPL), and Karnataka Antibiotics & Pharmaceutical Ltd (KAPL), he added. The government has offered voluntary retirement benefits to allemployees of IDPL and RDPL, Gowda said. "However, the Committeeof Ministers constituted on September 9, 2019, will take necessary decisions pertaining toclosure/strategic sale of the ...

PE firm Advent International acquires 51% stake in ZCL Chemicals

ZCL is one of the fastest-growing manufacturers of specialty active pharmaceutical ingredients (APIs) and advanced intermediates

Indian pharma market expected to hit $130 billion by 2030: Sadananda Gowda

The Indian pharmaceutical industry has proved to be a dependable supplier of quality drugs in a time of global need on account of the COVID-19 pandemic, and is expected to reach a size of USD 130 billion by 2030,Chemical and Fertiliser Minister D V Sadananda Gowda said on Monday. Following the onset of the pandemic, the Indian pharma industry has shown its role as a reliable supplier of drugs and medical devices in a time of need,he added. "The total market size of the Indian pharma industry is expected to reach USD 130 billion by 2030. The medical devices industry in India has the potential to grow at 28 per cent per annum to reach USD 50 billion by 2025," Gowda said. He wasaddressingthe curtain raiser press conference on the 6th edition of 'Indian Pharma & India Medical Device 2021'. "India has been serving more than 200 countries with its pharma products and will continue to discharge its responsibilities. We intend tocontinue formulating plans that are based on sound science, .